Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare the efficacy and safety of once-weekly semaglutide 1.0 mg s.c. with exenatide extended release (ER) 2.0 mg s.c. in subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS: In this phase 3a, open-label, parallel-group, randomized controlled trial, 813 subjects with type 2 diabetes taking oral antidiabetic drugs were randomized (1:1) to semaglutide 1.0 mg or exenatide ER 2.0 mg for 56 weeks. The primary end point was change from baseline in HbA1c at week 56. RESULTS: Mean HbA1c (8.3% [67.7 mmol/mol] at baseline) was reduced by 1.5% (16.8 mmol/mol) with semaglutide and 0.9% (10.0 mmol/mol) with exenatide ER (estimated treatment difference vs. exenatide ER [ETD] –0.62% [95% CI –0.80, –0.44] [–6.78 mmol/mol (95% CI –8.70, –4.86)]; P < 0.0001 for noninferiority and superiority). Mean body weight (95.8 kg at baseline) was reduced by 5.6 kg with semaglutide and 1.9 kg with exenatide ER (ETD –3.78 kg [95% CI –4.58, –2.98]; P < 0.0001). Significantly more subjects treated with semaglutide (67%) achieved HbA1c <7.0% (<53 mmol/mol) versus those taking exenatide ER (40%). Both treatments had similar safety profiles, but gastrointestinal adverse events were more common in semaglutide-treated subjects (41.8%) than in exenatide ER–treated subjects (33.3%); injection-site reactions were more frequent with exenatide ER (22.0%) than with semaglutide (1.2%). CONCLUSIONS: Semaglutide 1.0 mg was superior to exenatide ER 2.0 mg in improving glycemic control and reducing body weight after 56 weeks of treatment; the drugs had comparable safety profiles. These results indicate that semaglutide treatment is highly effective for subjects with type 2 diabetes who are inadequately controlled on oral antidiabetic drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“None of the current DM medications associated with weight loss, including GLP-1 RAs and SGLT2is, have resulted in more than 5.6% weight loss in clinical trials, and this includes dulaglutide,765 exenatide,766 exenatide-ER,767 liraglutide 1.8 mg,768 lixisenatide,769 semaglutide 1.0 mg/week,770,771 semaglutide 1.0 mg/week added to SGLT2i,772 oral semaglutide 14 mg,773 canagliflozin,774 dapagliflozin”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [766]
In the citing paper
“Study designs for these double-blind, randomized controlled trials have been published previously [18–21].”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [18]
In the citing paper
“Semaglutide by subcutaneous injection was shown to be superior to exenatide once weekly, dulaglutide, and liraglutide in lowering HbA1c.19”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [19]
In the citing paper
“Serum calcitonin was measured during these trials, and no notable difference in mean levels was seen between the treatment arms.”
From Safety of Semaglutide (2021) · cites this paper as [22]
In the citing paper
“None of these were medullary carcinoma.”
From Safety of Semaglutide (2021) · cites this paper as [22]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“GLP-1 RAs also reduce body weight by inducing feelings of satiety and fullness and reducing feelings of hunger, thereby lowering energy intake (3,4).”
BackgroundSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 2×
“mology to native human GLP-1 and is structurally similar to liraglutide (10), but important structural modifications make it less susceptible to degradation by dipeptidyl peptidase-4 and increase its specific high-affinity binding to albumin (10).”
BackgroundDeclaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects
World Medical Association (WMA) (2009) · Jahrbuch für Wissenschaft und Ethik · doi:10.1515/9783110208856.233 · Cited by 1,087
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Cited by
Items 201–300 of 657
Barać, M., & Roganović, J. (2025) · Biology · doi:10.3390/biology14121650 · Cited by 32
Gæde, P., Johansen, P., Tikkanen, C. K., Pollock, R. F., Hunt, B., & Malkin, S. J. P. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0630-6 · Cited by 32
Shi, A., Xie, P., Nielsen, L. L., Skjøth, T. V., He, X., & Haugaard, S. P. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01548-y · Cited by 32
Tilinca, M. C., Tiucă, R. A., Niculas, C., Varga, A., & Ţilea, I. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10601 · Cited by 34
The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs
Rodbard, H. W. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0103 · Cited by 30
Johansen, P., Håkan‐Bloch, J., Liu, A. R., Bech, P. G., Persson, S., & Leiter, L. A. (2019) · PharmacoEconomics - Open · doi:10.1007/s41669-019-0131-6 · Cited by 32
GLP-1 receptor agonists and cardiovascular protection: A class effect or not?
Scheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.12.009 · Cited by 32
Morieri, M. L., Rigato, M., Frison, V., Simioni, N., D'Ambrosio, M., Tadiotto, F., Paccagnella, A., Lapolla, A., Avogaro, A., & Fadini, G. P. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154190 · Cited by 31
Ding, Y., Shi, Y., Guan, R., Yan, S., Liu, H., Wang, Z., Li, J., Wang, T., Cai, W., & Ma, G. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2023.107031 · Cited by 31
Williams, D. M., Ruslan, A. M., Khan, R., Vijayasingam, D., Iqbal, F., Shaikh, A., Lim, J., Chudleigh, R., Peter, R., Udiawar, M., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01015-z · Cited by 31
Jordy, A. B., Albayaty, M., Breitschaft, A., Anderson, T. W., Christiansen, E., Houshmand-Øregaard, A., Manigandan, E., & Bækdal, T. A. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00976-x · Cited by 27
Li, Y., & Rosenblit, P. D. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1051-2 · Cited by 31
Pratley, R. E., Aroda, V. R., Catarig, A., Lingvay, I., Lüdemann, J., Yildirim, E., & Viljoen, A. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-037883 · Cited by 31
Self-citationGraybill, S. D., Hatfield, J., Kravchenko, M. I., Beckman, D., Tate, J. M., Beauvais, A., CLERC, P. G., Davila, D., Forbes, W. L., Wardian, J., et al. (2021) · Andrology · doi:10.1111/andr.12966 · Cited by 31
Butucă, A., Dobrea, C. M., Arseniu, A. M., Frum, A., Chiş, A. A., Rus, L. L., Ghibu, S., Juncan, A. M., Muntean, A. C., Lazăr, A. E., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12051124 · Cited by 31
Gomez-Peralta, F., & Abreu, C. (2019) · Drug Design, Development and Therapy · doi:10.2147/dddt.s165372 · Cited by 27
Lingvay, I., Capehorn, M., Catarig, A., Johansen, P., Lawson, J., Sandberg, A., Shaw, R., & Paine, A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa577 · Cited by 31
Self-citationSemaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
MacIsaac, R. J. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2511412 · Cited by 30
Billings, L. K., Andreozzi, F., Frederiksen, M., Gourdy, P., Gowda, A., Ji, L., Pletsch‐Borba, L., Suzuki, R., Unnikrishnan, A. G., & Vianna, A. G. D. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00052-x · Cited by 30
Morieri, M. L., Avogaro, A., & Fadini, G. P. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s216054 · Cited by 25
Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes
Ng, E., Shaw, J. E., Wood, A. J., Maple-Brown, L. J., & Hare, M. J. L. (2022) · Australian Journal of General Practice · doi:10.31128/ajgp-07-21-6057 · Cited by 30
Wu, W., Tong, H.-M., Li, Y., & Cui, J. (2023) · Endocrine · doi:10.1007/s12020-023-03636-9 · Cited by 30
Antza, C., Nirantharakumar, K., Doundoulakis, I., Tahrani, A. A., & Toulis, K. A. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s166765 · Cited by 30
Mishriky, B. M., Cummings, D. M., Powell, J. R., Sewell, K. A., & Tanenberg, R. J. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.09.002 · Cited by 27
Menzen, M., Berentzen, T. L., Catarig, A.-M., Pieperhoff, S., Simon, J., & Jacob, S. (2023) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2007-2061 · Cited by 29
Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
Di Folco, U., Vallecorsa, N., Nardone, M. R., Pantano, A. L., & Tubili, C. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01936-6 · Cited by 29
Mullins, G. R., Hodsdon, M. E., Li, Y. G., Anglin, G., Urva, S., Schneck, K. B., Bardos, J. N., Martins, R. F., Brown, K. E., & Calderón, B. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad532 · Cited by 29
Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity
Yazıcı, D., Eser, H. Y., Kiyici, S. K., Sancak, S., Sezer, H., Uygur, M., & Yumuk, V. (2022) · Obesity Facts · doi:10.1159/000526808 · Cited by 29
Li, X., Qie, S., Wang, X., Zheng, Y., Liu, Y., & Liu, G. (2018) · Endocrine · doi:10.1007/s12020-018-1708-z · Cited by 29
Berra, C. C., Rossi, M. C., Mirani, M., Ceccarelli Ceccarelli, D., Romano, C., Sassi, L., Peretti, E., Favacchio, G., Pastore, I., Folini, L., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1099451 · Cited by 28
Ikushima, I., Jensen, L., Flint, A., Nishida, T., Zacho, J., & Irie, S. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0677-1 · Cited by 28
Hu, S., Su, X., & Fan, G. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01195-7 · Cited by 28
Anastasiou, I. A., Argyrakopoulou, G., Dalamaga, Μ., & Kokkinos, A. D. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00623-1 · Cited by 29
Fadini, G. P., Bonora, B. M., Ghiani, M., Anichini, R., Melchionda, E., Fattor, B., Fazion, S., Meregalli, G., Giaccari, A., Avogaro, A., et al. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15554 · Cited by 27
Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management
Powell, J., & Taylor, J. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.12.014 · Cited by 27
Alexopoulos, A.-S., & Buse, J. B. (2019) · Metabolism · doi:10.1016/j.metabol.2019.06.012 · Cited by 24
Zhong, P., Zeng, H., Huang, M., He, G., & Chen, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.695182 · Cited by 27
Pharmacological profile of once-weekly injectable semaglutide for chronic weight management
Lau, D. C. W., Batterham, R. L., & le Roux, C. W. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2070473 · Cited by 27
Wolffenbuttel, B. H. R., Brugts, M. P., Catarig, A.-M., Clark, A., Kok, M., Lieverse, A. G., & van Soest, J. (2023) · Advances in Therapy · doi:10.1007/s12325-022-02385-x · Cited by 26
Stretton, B., Kovoor, J., Bacchi, S., Chang, S., Ngoi, B., Murray, T., Bristow, T. C., Heng, J., Gupta, A., Ovenden, C., et al. (2023) · Internal Medicine Journal · doi:10.1111/imj.16126 · Cited by 26
New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
Ni, X., Zhang, L., Feng, X., & Tang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.877797 · Cited by 27
Sarzani, R., Landolfo, M., Pentima, C. D., Ortensi, B., Falcioni, P., Sabbatini, L., Massacesi, A., Rampino, I., Spannella, F., & Giulietti, F. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1365183 · Cited by 26
DeVries, J. H., Desouza, C., Bellary, S., Unger, J., Hansen, O. K. H., Zacho, J., & Woo, V. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13396 · Cited by 24
Treatment of Hypothalamic Obesity With GLP-1 Analogs
Dimitri, P., & Roth, C. L. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae200 · Cited by 25
Aroda, V. R., Jørgensen, N. B., Kumar, B., Lingvay, I., Laulund, A. S., Buse, J. B., & trial investigators (2025) · Diabetes Care · doi:10.2337/dc24-2425 · Cited by 25
Self-citationJabbour, S. A., Paik, J. S., Aleppo, G., Sharma, P., Valderas, E. G., & Benneyworth, B. D. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.05.005 · Cited by 26
An, X., Sun, W., Wen, Z., Duan, L., Zhang, Y., Kang, X., Ji, H., Sun, Y., Jiang, L., Zhao, X., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16228 · Cited by 25
Davies, M. J., Bianchi, C., & Del Prato, S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154242 · Cited by 23
Mohammedi, K., Belhatem, N., Berentzen, T. L., Catarig, A., & Potier, L. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15045 · Cited by 25
Camilleri, M. (2023) · Neurogastroenterology & Motility · doi:10.1111/nmo.14660 · Cited by 25
Effectiveness and safety of GLP-1 agonist in obese patients with inflammatory bowel disease
Belinchón, C. R., Martínez-Lozano, H., Serrano‐Moreno, C., Castillo, D. H., Chicharro, P. L., Ocampo, P. F., Marín‐Jiménez, I., Lesmes, I. B., & Menchen, L. A. (2024) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2024.10305/2024 · Cited by 25
Ericsson, Å., & Fridhammar, A. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1614009 · Cited by 25
Chudleigh, R. A., Platts, J. K., & Bain, S. C. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s193693 · Cited by 25
Yabe, D., Yamada, Y., Kaku, K., Nishida, T., Sato, T., & Seino, Y. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13773 · Cited by 24
Martínez, J. J. G., Malkin, S. J. P., Martín, V., Hallén, N., & Hunt, B. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1681436 · Cited by 24
Bellido, V., Padín, C. A., Catarig, A., Clark, A., Pittol, S. B., & Delgado, E. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11174938 · Cited by 24
Hansen, K. B., Svendstrup, M., Lund, A., Knop, F. K., Vilsbøll, T., & Vestergaard, H. (2021) · Diabetic Medicine · doi:10.1111/dme.14655 · Cited by 23
Semaglutide treatment of hypothalamic obesity – a real-life data study
Svendstrup, M., Rasmussen, A. K., Kistorp, C., Klose, M., & Andreassen, M. (2024) · Pituitary · doi:10.1007/s11102-024-01429-5 · Cited by 23
“Other extrahypothalamic effects of GLP-1 have been identi�ed in the orbitofrontal cortex, the striatum, the area postrema and the insula [36, 37].”
BackgroundRayner, C. K., Wu, T., Aroda, V. R., Whittington, C., Kanters, S., Guyot, P., Shaunik, A., & Horowitz, M. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14202 · Cited by 23
Self-citationBuonanno, S., Gaggiano, C., Terribili, R., Cantarini, L., Frediani, B., & Gentileschi, S. (2025) · Inflammation Research · doi:10.1007/s00011-025-02140-2 · Cited by 23
Structured lifestyle modification as an adjunct to obesity pharmacotherapy: there is much to learn
Murphy, E. E., & Finucane, F. M. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01499-2 · Cited by 23
Molecular and Materials Engineering for Delivery of Peptide Drugs to Treat Type 2 Diabetes
Varanko, A. K., & Chilkoti, A. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801509 · Cited by 23
Di Loreto, C., Minarelli, V., Nasini, G., Norgiolini, R., & Del Sindaco, P. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01218-y · Cited by 21
Dalmazi, G. D., Coluzzi, S., BALDASSARRE, M. P. A., Ghit, A., Graziano, G., Rossi, M. C., Ciappini, B., Milo, M., Carrieri, F., Nicolucci, A., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.892702 · Cited by 22
Kurtzhals, P., Kreiner, F. F., & Bindra, R. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110881 · Cited by 22
Catrina, S., Amadid, H., Braae, U. C., Dereke, J., Ekberg, N. R., Klanger, B., & Jansson, S. P. O. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01614-6 · Cited by 22
Anti-atherosclerotic effect of incretin receptor agonists
Wang, X., Yang, X., Qi, X., Fan, G., Zhou, L., Peng, Z., & Yang, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1463547 · Cited by 22
Hydrocarbon-Stitched Peptide Agonists of Glucagon-Like Peptide‑1 Receptor
Bird, G. H., Fu, A., Escudero, S., Godes, M., Opoku-Nsiah, K., Wales, T. E., Cameron, M. D., Engen, J. R., Danial, N. N., & Walensky, L. D. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00308 · Cited by 22
Buse, J. B., Christensen, H. N., Harty, B. J., Mitchell, J., Soule, B. P., Zacherle, E. W., Cziraky, M. J., & Willey, V. J. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003206 · Cited by 21
Glucagon-like Peptide-1 Agonists: What the Orthopaedic Surgeon Needs to Know
Chan, P. Y. W., Mika, A. P., Martin, J. R., & Wilson, J. M. (2024) · JBJS Reviews · doi:10.2106/jbjs.rvw.23.00167 · Cited by 21
Wen, J., Nadora, D., Bernstein, E., How-Volkman, C., Truong, A., Akhtar, M., Prakash, N. A., Puglisi, J. L., & Frezza, E. E. (2024) · Cureus · doi:10.7759/cureus.69008 · Cited by 21
GLP-1R in diabetes mellitus: from basic discovery to therapeutics development
Li, S., Huang, N., Wang, M., Huang, W., Luo, Y., & Huang, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1610512 · Cited by 21
Doggrell, S. A. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1441286 · Cited by 21
Jendle, J., Birkenfeld, A. L., Polonsky, W. H., Silver, R., Uusinarkaus, K., Hansen, T., Håkan‐Bloch, J., Tadayon, S., & Davies, M. J. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13816 · Cited by 19
Treatment Options for Poor Responders to Bariatric Surgery
Lee, P. C., Dixon, J. B., Sim, P. Y., & Lim, C. H. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00381-2 · Cited by 21
Bain, E. K., & Bain, S. C. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14487 · Cited by 20
de Lucas, M. D. G., Miramontes‐González, J. P., Avilés, B., Jiménez-Millán, A. I., Rivas‐Ruiz, F., & Perez-Belmonte, L. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.995646 · Cited by 21
Malkin, S. J. P., Russel-Szymczyk, M., Liidemann, G., Volke, V., & Hunt, B. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0542-x · Cited by 21
Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus
Lee, J., Kim, R., Kim, M.-H., Lee, S.-H., Cho, J.-H., Lee, J. M., Jang, S.-A., & Kim, H.-S. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.07.006 · Cited by 20
Tilinca, M. C. (2023) · FARMACIA · doi:10.31925/farmacia.2023.1.1 · Cited by 20
Sun, Q., Liu, J., Meng, R., Zhang, N., Yao, J., Yang, F., & Zhu, D. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14026 · Cited by 20
Khan, T. T. S., Sheikh, Z., Maleknia, S. D., Oveissi, F., Fathi, A., Abrams, T., Ong, H. X., & Traini, D. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2387110 · Cited by 21
Yale, J., Major‐Pedersen, A., Catarig, A., Jain, R., Menzen, M., & Holmes, P. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15794 · Cited by 20
Hurren, K. M., & Dunham, M. W. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1494727 · Cited by 20
Handelsman, Y., Wyne, K., Cannon, A., Shannon, M., & Schneider, D. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.9-a.s14 · Cited by 14
The efficacy and safety of exenatide once weekly in patients with type 2 diabetes
Heimbürger, S. M. N., Brønden, A., Johansen, N. J., Dejgaard, T. F., Vilsbøll, T., & Knop, F. K. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1571040 · Cited by 20
Rodbard, H. W., Bellary, S., HRAMIAK, I. M., Seino, Y., Silver, R., Damgaard, L. H., Nayak, G., Zacho, J., & Aroda, V. R. (2019) · Endocrine Practice · doi:10.4158/ep-2018-0444 · Cited by 20
Self-citationEfficacy of semaglutide versus liraglutide in clinical practice
Gonçalves, E., & Bell, D. S. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.10.001 · Cited by 20
Exploring beyond numeric weight loss: The metabolic effects of semaglutide
Sokary, S., & Bawadi, H. A. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.03.010 · Cited by 20
Kanters, S., Wilkinson, L., Vražić, H., Sharma, R., Lopes, S. H. K., Popoff, E., & Druyts, E. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-023458 · Cited by 19
Petroni, M. L., Montesi, L., Colosimo, S., Caletti, M. T., Mazzotti, A., & Marchesini, G. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.82 · Cited by 19
Capehorn, M., Ghani, Y., Hindsberger, C., Johansen, P., & Jódar, E. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00796-z · Cited by 19
Self-citationSwitch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study
Hepprich, M., Zillig, D., Florian-Reynoso, M. A., Donath, M. Y., & Rudofsky, G. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01016-y · Cited by 18
Witkowski, M., Wilkinson, L., Webb, N., Weids, A., Glah, D., & Vrazic, H. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0428-y · Cited by 18
Ali, S., Baig, S., Wanninayake, S., Xavier, G. D. S., Dawson, C., Paisey, R., & Geberhiwot, T. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15398 · Cited by 19
Chae, Y., Kwon, S., Nam, J. H., Kang, E., Im, J., Kim, H.-J., & Lee, E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2363838 · Cited by 18
Douros, J. D., Flak, J. N., & Knerr, P. J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1530985 · Cited by 18
Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes
Tuchscherer, R. M., Thompson, A. M., & Trujillo, J. M. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018784583 · Cited by 18
Martínez, J. J. G. (2019) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2019.03.005 · Cited by 19
Napoli, R., Avogaro, A., Formoso, G., Piro, S., Purrello, F., Targher, G., & Consoli, A. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.08.039 · Cited by 18
Metadata
- Authors
- Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R.
- Affiliations
- Oregon Health & Science University (US)
- Rotherham Institute for Obesity, Clifton Medical Centre, Rotherham, U.K.
- Centre Hospitalier Sud Francilien (FR)
- University of Siena (IT)
- GWT-TUD GmbH (Germany) (DE)
- The University of Texas Southwestern Medical Center (US)
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk Inc., Plainsboro, NJ
- MedStar Health Research Institute (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-12-15
- Volume
- 41
- Issue
- 2
- Pages
- 258-266
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2774157762
- Cited by
- 596
- References
- 32
- Citations by year
- 2026: 57 · 2025: 91 · 2024: 88 · 2023: 68 · 2022: 68 · 2021: 48 · 2020: 64 · 2019: 55 · 2018: 51 · 2017: 3
- FWCI
- 37.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, exenatide extended-release, type 2 diabetes, GLP-1 receptor agonists, glycemic control, HbA1c, weight loss, gastrointestinal adverse effects, injection site reactions, non-inferiority, oral antidiabetic drugs, drug safety and efficacy comparison, weekly dosing
- MeSH terms
- Exenatide, Semaglutide, Adult, Aged, Aged, 80 and over, Blood Glucose, Body Weight, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Drug Administration Schedule, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Venoms, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.